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Across all patients, children ages 0-4 years (P¼ .01) and 5-12
years (P¼ .001) predicted CRV infection. The allo group had
the greatest incidence of CRV infection (16%), and were most
sensitive to the presence of young children. Total number of
household members was not a predictor of CRV. The mean
number of days to CRV infection for all groups was 283 days
post-transplant.
Conclusions: Households with children in the age groups
of 0-4 and 5-12 more than doubled the risk of an HSCT
patient acquiring a CRV infection. Further studies are
needed to test interventions designed to interrupt house-
hold transmission of CRV from children to the vulnerable
HSCT patient. Household contacts, especially children,
should be included in transplant teaching. As indicated by
the potentially high number of days between transplant
and CRV infection, re-education and continuing focus on
CRV prevention should be reinforced throughout the post-
transplant period.
*0-4 year age group P¼ .01
**5-12 year age group P¼ .001539
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Serving as a caregiver for someone undergoing intense
cancer treatments, such as allogeneic transplantation, has
beneﬁts but also carries unavoidable psychological and
emotional effects, which may include loneliness. Loneliness
is deﬁned as feeling isolated or alone when one desires
connections with others. Cross-sectional data were drawn
from hematopoietic stem cell transplant (HSCT) caregivers
(CG) (n¼21) and matched (age, gender, race/ethnicity) non-
caregiver controls (MC) (n¼20) to examine their level of
loneliness and related factors.
Methods: Adult HSCT CGs literate in English/Spanish, pre-
HSCT, completed the Health Promoting Lifestyle Proﬁle-II,
General Self Efﬁcacy scale, PROMIS short forms and UCLA
Loneliness scale.Results: CGs were primarily female (66.7%), 50.8 years old
(+ 11.9) and spouse of the HSCT recipient (52.4%). Thirteen
(61.9%) were sole CGs while 38.1% were members of a CG
‘network’. Adult patients were preparing for a reduced
intensity (61.9%), peripheral blood (95.2%) related donor
(85.7%) HSCT for lymphoma (28.6%) or leukemia (33.3%).
CG loneliness scores were signiﬁcantly higher (p¼0.022)
than MCs (20.86 + 5.7 vs. 17.0 + 4.6), with male CGs
signiﬁcantly higher than male MCs. Sole male CGs who
were spouses reported highest loneliness scores. Loneli-
ness was signiﬁcantly related (P < .05) to interpersonal
relations, spiritual growth and self-efﬁcacy, suggesting CGs
with well-established relationships, spiritual connections
and conﬁdence in their caregiving abilities were less
lonely.
Conclusion: Conﬁdence as a CG is critical for HSCT patient
recovery but also CG well-being. Assessing loneliness in
HSCT CGs may be of value especially in groups at risk for
loneliness. Future research should explore interventions
that modify health behaviors such as developing relation-
ships and enhancing self-efﬁcacy in CGs and HSCT
recipients.
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Introduction: The area-under-the curve (AUC) for busulfan
has been linked to clinical outcomes such as veno-occlusive
disease (VOD) and cancer relapse. The choice of body weight
(actual versus adjusted weight) to calculate the dose of
busulfan may be critical in attaining goal AUC based on
pharmacokinetic (PK) analysis, especially for overweight
patients.
Objective: Determine a correlation between weight chosen
for dosing of busulfan and outcomes.
Methods: An IRB-approved retrospective analysis was per-
formed on hematopoietic stem cell transplant (HSCT)
recipients who had received either Q6H IV busulfan with
cyclophosphamide (Bu/Cy) or once-daily IV busulfan with
ﬂudarabine (Flu/Bu) as conditioning regimens. All patients
underwent prospective monitoring of serum PKs at
a specialized therapeutic drug monitoring central laboratory.
Data was analyzed using Systat ver 13.
Results: Of the 31 patients with evaluable PK results, mean
age was 53 years; 48% were male; 77% were Caucasian and
58% had AML/MDS. GVHD prophylaxis consisted of tacroli-
mus/methotrexate in 58% and tacrolimus/mini-metho-
trexate in 42% of patients; 35% of the patients also received
anti-thymocyte globulin. With regards to conditioning
regimen, 58% received Flu/Bu (50% dosed on actual weight,
50% dosed on adjusted) and 42% received Bu/Cy (23% ¼
actual weight, 77% ¼ adjusted). Only two patients did not
require a dose adjustment based on AUC results. Overall,
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under-shoot the goal AUC (-12.8 % vs. +19.5 %, P ¼ .018), and
require busulfan dose increases (+20% vs. -19.9%, P ¼ .012)
compared to those dosed on actual body weight. A subgroup
analysis conﬁrmed this result for patients receiving Bu/Cy
(-23.6 % vs. +2.2%, P ¼<.001 for goal AUC and +36.2% vs. -4.5
%, P ¼ .008 for busulfan dose changes in adjusted vs. actual
body weight groups, respectively), but not Flu/Bu condi-
tioning regimens (-0.8 % vs. +25.3%, P¼ .123 for goal AUC and
+3.4% vs. -25.1 %, P ¼ .174 for busulfan dose changes in
adjusted vs. actual body weight groups, respectively).
Notably, two patients dosed by actual body weight in the Flu/
Bu group experienced an AUC of > 9000 mmol*min. Time to
neutrophil or platelet engraftment, progression-free survival
and overall survival were not signiﬁcantly different between
those dosed on actual versus adjusted body weight (P > .05).
No neurologic adverse events or VOD incidents were
observed in any group.
Conclusions: Our prospective analysis of IV busulfan
PK data in various myeloablative and non-myeloablative
busulfan based conditioning regimens for HSCT provides
important insight into the choice of appropriate busulfan
dosing weight. Further studies are warranted to elucidate
which weight is most likely to achieve goal area-
under-the curve and subsequent optimal patient
outcomes.541
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Background: Etoposide is an important drug in the
conditioning regimen for hematopoietic stem cell trans-
plant (HSCT). The administration of etoposide in this
patient care setting presents a challenge due to limited
aqueous solubility. As a result of the high doses utilized in
myeloablative regimens, administration is accompanied
by large volumes of intravenous ﬂuids which increase
the risk for volume overload, cardiac dysfunction, and
electrolyte abnormalities. There are published reports
that describe unchanged pharmacokinetic parameters
between diluted and undiluted drug, as well as data
describing the safe use of undiluted drug in the transplant
population.
Methods: We report our experience with eleven patients
who received undiluted etoposide (20 mg/mL) over 4 hours
through a central line in preparation for HSCT. All patients
received an antihistamine and corticosteroid as premed-
ication, as well as another dose of each and acetaminophen
when half of the volume had infused. The etoposide was
infused through DEHP-free tubing into a dedicated lumen.
Vital signs were monitored at baseline, regularly
throughout the infusion, and after the infusion was
complete.
Results: Between April 2 and June 15, 2012, eleven
patients received undiluted etoposide at a dose of 60 mg/
kg. The most common adverse events documented were
gastrointestinal toxicities. All patients reported nausea
and most cases were accompanied by emesis, requiring an
average of 4.4 antiemetic doses for treatment of break-
through nausea/vomiting. Hypotension was documentedin nine patients, with an average drop in systolic blood
pressure of 35 mm Hg (range: 15-46 mm Hg) occurring 6.6
hours (range: 1.7-18.8 hours) after the start of etoposide
infusion. Nine patients required ﬂuid resuscitation with an
average of 1400 mL (range: 500 mL-3500 mL) of normal
saline.
Conclusion: Despite published reports of successful
administration of undiluted etoposide in myeloablative
conditioning regimens, we report numerous adverse events
in our patient population. All patients treated at our insti-
tution with undiluted etoposide as part of the conditioning
regimen experienced side effects related to the drug. The
beneﬁts of administering undiluted etoposide should be
carefully weighed against the possibility of related tox-
icities.542
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Introduction: Antifungal prophylaxis with azoles is con-
sidered standard in patients undergoing allo-HCT. However,
azoles have signiﬁcant interactions with immunosuppres-
sive drugs used for graft-versus-host disease (GVHD)
prophylaxis. Since the risk of GVHD is increased in the
setting of sub-therapeutic immunosuppressant levels, we
changed our standard practice from initiating the triazole on
day +3 to day +7 after allo-HCT in order to make the change
at steady state and limit the occurrence of non-therapeutic
levels.
Methods:We retrospectively evaluated 196 patients treated
from Jan 2009 to Nov 2011 to assess the impact of delaying
the start of azole antifungals on immunosuppressive levels,
acute GVHD, and rate of invasive fungal infections (IFI).
Micafungin was given from admission until azole initiation.
Patients received voriconazole (n¼162), posaconazole
(n¼17), ﬂuconazole (n¼9) or were maintained on mica-
fungin (n¼8). Stem cell sources included PBSCT from
related/unrelated donors (n¼139) and cord blood grafts
(n¼57). GVHD prophylaxis was with tacrolimus (tacro) +
sirolimus (siro) + methotrexate (MTX) (n¼76), tacro + MTX
(n¼42), cyclosporine (CSA) + mycophenolate mofetil (MMF)
(n¼57), tacro + MMF (n¼9), tacro + siro (n¼7), CSA + MTX
(n¼3), CSA (n¼1), siro + MMF (n¼1). Results were analyzed
by intent-to-treat (ITT) for patients treated before (day+3
switch, n¼69) or after February 2010 (day+7 switch, n¼127)
as well as by actual day of switch + 1 (day+2,3,4: n¼49 vs.
day+6,7,8: n¼70). Cumulative incidence (CI) functions esti-
mated day 200 grade II-IV aGVHD. Gray's test was used to
compare aGVHD incidence for individuals in the day +3 and
day+7 treatment categories for both the ITT and as-treated
analyses.
Results: Median levels two weeks after HCT were thera-
peutic in 19/19 (100%), 50/52 (96%), 31/32 (97%) patients on
CSA, Tacro, and Siro, respectively, prior to Feb 2010 and in
43/44 (98%), 82/83 (99%), 47/52 (90%), for CSA, Tacro, and
